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Purpose: The desired outcome in schizophrenia treatment has evolved from symptom 
  management to maximization of quality of life and functional recovery. The aim of this study 
was to assess the relationship between a specific well-being measure, the Subjective Well-being 
under Neuroleptic Scale – short version (SWN-K), and the SF-36 Health Survey as a generic 
quality of life measure.
Patients and methods: A multicenter, cross-sectional study was conducted with clinically 
stable outpatients diagnosed with schizophrenia. Spearman’s rank correlation was used to assess 
the associations between the SWN-K total score, its five subscales, and the SF-36 domains.
Results: Ninety-seven patients were included in the study. The mean age was 35 years (standard 
deviation = 10) and 72% were male. All correlations among domains were positive and most 
were statistically significant. The bodily pain domain of the SF-36 presented the lower cor-
relations with the SWN-K (rho range 0.10–0.25), whereas the other seven domains correlated 
significantly (rho range 0.49–0.60, all P , 0.001). The largest correlations were obtained between 
the SWN-K and the SF-36 domains of general health (rho = 0.53), mental health (rho = 0.60), 
and vitality (rho = 0.54).
Conclusion: The positive but nevertheless moderate correlations observed between a specific 
well-being instrument and a generic quality of life scale supports the inclusion of diagnosis-
specific tools for outcome assessment of patients with schizophrenia.
Keywords: schizophrenia, subjective well-being, quality of life, patient-reported outcomes, 
generic health status measures, SF-36
Introduction
In parallel to the steady improvement in treatment of patients with schizophrenia, the 
desired outcome has evolved from symptom management to maximization of quality 
of life and functional recovery.1
Generic health status measures such as the EuroQol-5D and the SF-36 Health 
Survey (SF-36) are increasingly being used to inform health policy.2,3 They are admin-
istered in several diseases and their use is spreading in mental health research.4 There 
is an increasing awareness of the need to address mental health as an integral part of 
improving worldwide population health.5 The self-perception of patients with severe 
mental disorders is a key factor in adherence, quality of life, and clinical outcome.6 
However, information on the relationship between different aspects of mental health, 
subjective well-being, and physical health is lacking.
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The aim of this study was to assess the relationship 
between a specific well-being measure, the Subjective Well-
Being under Neuroleptic scale – short version (SWN-K),7 
and the eight domains of the public version of the SF-36 v1 
as a generic quality of life measure.
Material and methods
A non-interventional, cross-sectional study was conducted 
in 20 mental health centers throughout Spain. The study was 
approved by the institutional review board of the Fundació 
Sant Joan de Deu (Barcelona, Spain). Written informed 
consent was obtained from all patients. The criteria for 
patient recruitment were: 18–65 years of age; a diagnosis 
of schizophrenia, schizoaffective disorder, or schizophreni-
form disorder, according to the Diagnostic and Statistical 
Manual of Mental Disorder: Fourth Edition; Text Revision; 
follow-up as an outpatient; and clinically stable as judged 
by the investigators.
The SWN-K is a self-rated scale consisting of 20 items 
with a six-point Likert response format, capturing subjec-
tive experiences of patients during antipsychotic treatment. 
It consists of five subscales: physical and mental functioning, 
self-control, emotional regulation, and social   integration. 
Total scores range from 20 to 120 points, with higher 
scores indicating greater well-being.7,8 This questionnaire 
has been used in several studies to assess quality of life in 
  schizophrenia from a patient’s perspective.6,9
Patients completed the Spanish version of the SF-36 
Health Survey, a self-reported multidimensional survey 
measure of health-related quality of life.3 The question-
naire contains 36 items and addresses eight health domains: 
  physical functioning, role limitations due to physical 
health, bodily pain, general health perceptions, vitality, 
social functioning, role limitations due to emotional prob-
lems, and mental health. It can usually be completed in 
5–10 minutes.10
In addition, the investigators completed the Positive 
and Negative Syndrome Scale and the Clinical Global 
Impression – Severity Scale in order to assess the clinical 
status of the sample.
Demographic and clinical characteristics were described 
using mean, standard deviation (SD), and a 95% confidence 
interval for continuous measures. Spearman’s rank correla-
tion test was used to assess associations between SWN-K 
total score, its five subscales, and the SF-36 domains. The 
SF-36 estimates were calculated using public code (SF36 
v2.2.2 Stata ado, written by Philip Ryan).
Results
A total of 97 patients were included in the statistical 
analysis. The mean age was 35 years (SD = 10), and males 
accounted for 72% of the sample. Most patients had a diag-
nosis of schizophrenia (n = 77), followed by schizoaffective 
  disorder (n = 18), and schizophreniform disorder (n = 2). 
  Demographic and clinical characteristics of the sample are 
shown in Table 1.
All correlations between domains were positive and 
most of them were statistically significant. As expected, 
the lowest correlations with the SWN-K were seen in the 
bodily pain domain of the SF-36 (rho range 0.10–0.25). On 
the other hand, all other SF-36 domains significantly corre-
lated with the SWN-K total score (rho range 0.49–0.60, all 
values of P , 0.001). The largest correlations were recorded 
between the SWN-K and the SF-36 domains of general 
health (rho = 0.53), mental health (rho = 0.60), and vitality 
(rho = 0.54) (Table 2).
Discussion
Outcomes research in patients with schizophrenia should take 
into account the subjective interpretation of the mood and physi-
cal changes that are usually associated with medication intake.1 
Agents involved in health technology assessment are already 
incorporating these other important aspects into the basic aims 
of discerning new treatments’ efficacy and safety.11 There is 
published evidence on the appropriateness and accuracy of self-
administered evaluations in patients with severe chronic mental 
disorders.12–14 These changes will influence behavioral response 
to treatment and ultimately the patient’s clinical outcome as 
mediated by their treatment compliance.6,15
Many efforts have been made to develop specific instru-
ments to assess patients’ affectation within different domains. 
Perception of quality of life may differ depending on the 
Table 1 Patient demographics and clinical characteristics
N = 97
Age (years), mean (SD) 35.0 (10.0)
Gender (male) (%) 72.0
Age at onset (years), mean (SD) 22.0 (8.0)
Married or cohabiting (%) 5.1
Number of hospitalizations (median) (SD) 3.0 (3.7)
Participating in psychoeducational programs (%) 46.9
CGI-S score (mean) (SD) 3.6 (1.3)
PANSS total score (mean) (SD) 65.0 (21.4)
SWN-K total score (mean) (SD) 83.5 (14.0)
Abbreviations: CGI-S, Clinical Global Impression – Severity scale; PANSS, Positive 
and Negative Syndrome Scale; SWN-K, Subjective Well-being under Neuroleptic 
scale – short version.
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Table 2 Spearman’s rank correlations between SWN-K and SF-36 domains
SF-36 domains
Physical  
functioning
General  
health
Vitality Mental  
health
Role  
physical
Role  
emotional
Social  
functioning
Bodily   
pain
SWN-K total score 0.50*** 0.53*** 0.54*** 0.60*** 0.52*** 0.52*** 0.49*** 0.25*
Mental functioning 0.41*** 0.46*** 0.48*** 0.50*** 0.41*** 0.45*** 0.41*** 0.20
Social integration 0.43*** 0.38*** 0.39*** 0.45*** 0.39*** 0.48*** 0.48*** 0.10
Emotional regulation 0.37*** 0.39*** 0.44*** 0.46*** 0.31** 0.33*** 0.23* 0.11
Physical functioning 0.44*** 0.50*** 0.46*** 0.60*** 0.51*** 0.40*** 0.37*** 0.25*
Self-control 0.28** 0.34*** 0.41*** 0.39*** 0.43*** 0.40*** 0.38*** 0.19
Notes: *P , 0.05; **P , 0.01; ***P , 0.001.
Abbreviations: SWN-K, Subjective Well-being under Neuroleptic scale – short version; SF-36, Short Form – 36 Health Survey.
patients’ perspective. Patients typically rate their utilities 
much higher than the general public or proxies, while phy-
sicians tend to give the lowest ratings.16 Therefore, more 
specific tools in terms of health-related quality of life are 
still needed.17,18
The positive but nevertheless moderate correlations 
noted between a specific well-being scale, the SWN-K, and 
a generic quality of life scale, such as the SF-36, support 
the inclusion of diagnosis-specific instruments for outcome 
assessment in patients with schizophrenia.
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